Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-1: Maridebart Cafraglutide in Obesity or Overweight
NCT06858839Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of maridebart cafraglutide in obesity, sponsored by Amgen. Started Mar 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06858839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858839.